This post-market clinical study is designed to evaluate the effectiveness of the Ultravision™ System when compared to the Airseal® iFS within an approved indication for use, namely laparoscopic cholosystectomy.
The primary hypothesis being tested in this study is that Ultravision facilitates the utilization of lower pneumoperitoneal pressures whilst maintaining an adequate visual field throughout the procedure with low demand for CO2 replenishment to maintain pneumoperitoneal pressure. Comparisons in terms of surgical field visualization, procedure times, and CO2 consumption will be conducted in order to determine whether or not any clinical benefits are derived from the use of the Ultravision™ System compared to the Airseal® iFS. Low pressure laparoscopy for this study is set at 10mmHg. This is a prospective, open-label, randomized controlled study. The study will include two study arms. Patients undergoing laparoscopic cholecystectomy will be randomized to either "Ultravision" (study arm 1) or Airseal® iFS (study arm 2). Both groups will conduct the procedure at 10mmHg, considered to be low pressure/low impact laparoscopic surgery. The study will enroll 30 patients, 15 per group. Both devices are being used according to their cleared label claims.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
Duke Regional Hospital
Durham, North Carolina, United States
RECRUITINGCarbon Dioxide Utilization
The volume measured in Liters of Carbon Dioxide consumed during the procedure
Time frame: Measured from Veress needle insertion to just prior to gall bladder removal
Quality of Visualization
The quality of visualization in the laparoscopic field
Time frame: Measured from camera insertion through removal
Procedure time for Diathermy use
Measures the procedure time in minutes where diathermy is used
Time frame: Measured from the exposure and identification of the cystic duct and artery is complete to the last use of diathermy
Diathermy Power Setting
Highest diathermy setting used during the procedure
Time frame: Measured from the exposure and identification of the cystic duct and artery is complete to the last use of diathermy
Procedure Time
Overall procedure time in minutes
Time frame: Measured from the insertion of the camera to the time of closure
End tidal CO2 Volume
End tidal volume of CO2
Time frame: Measured at Veress needle insertion and just prior to gall bladder removal
Laparoscope cleaning
The number of times during the procedure that the laparoscope must be removed for cleaning to maintain visual field
Time frame: Measured from the exposure and identification of the cystic duct and artery is complete to the last use of diathermy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pneumoperitoneum Pressure
The pneumoperitoneum pressure during the procedure and record of any increase beyond 10mmHg for visualization
Time frame: Starting pneumoperitoneum pressure at the time of camera trocar insertion, record the maximum pressure that occurred during the procedure
Trocar Venting
The number of times the trocar is used to vent during the procedure for visualization
Time frame: Measured from the exposure and identification of the cystic duct and artery is complete to the last use of diathermy
Case Complexity
Case complexity compared to surgeon experience. Recorded as simple or routine or complex/difficult.
Time frame: Immediately post-procedure
Pain Assessment
Pre and Post operative pain surveys
Time frame: Pre-procedure and 1 to 7 days post procedure
Pain Medications
Amount and type of pain medication administered and record of use following the procedure
Time frame: 1 to 7 days post procedure